About this Research Topic
Idiopathic Pulmonary Fibrosis (IPF) is a complex and heterogeneous lung disease characterized by progressive fibrosis of the lungs, leading to a decline in lung function and ultimately resulting in respiratory failure. Despite advances in the understanding of the disease, the current treatment options are limited and have limited effectiveness. Therefore, there is a strong need for new and more effective treatment strategies for IPF.
It is now well-established that both innate and adaptive immune response plays an important role in the pathology of IPF. This Research Topic aims to investigate the use of a multi-omics-based translational approach for precision medicine in IPF. This approach will involve the integration of multiple omics data -including genomics, transcriptomics, proteomics, and metabolomics- to gain a comprehensive understanding of the molecular mechanisms underlying IPF and to identify new therapeutic targets and biomarkers -including diagnostic, prognostic, subtype, drug-response, and side-effect-prediction biomarkers-.
In this Research Topic, we welcome research proposals focused on the use of multi-omics-based translational approaches for precision medicine in Idiopathic Pulmonary Fibrosis (IPF), including immune component analysis (immune cell, immune communication, cytokine, chemokine, and antigens analysis), in vitro and in vivo assays, significant computational methods, and platforms, successful applications, benchmarking datasets, workflows and pipelines, and integrative analysis of high-throughput datasets in this field. The Research Topic will cover, but is not limited to, the following:
1. Identification of novel therapeutic targets: Research focused on identifying new targets for treating IPF using multi-omics data, such as genome-wide association studies, transcriptomics, proteomics, and metabolomics.
2. Development of multi-omics-based diagnostic tests: Research focused on developing diagnostic tests that utilize multi-omics data to aid in diagnosing IPF.
3. Identification of biomarkers for IPF: Research focused on identifying biomarkers that can be helpful for the diagnosis and prognosis of subtype IPF using multi-omics data.
4. In vitro and in vivo validation of therapeutic targets: Research focused on validating novel therapeutic targets identified in multi-omics data using in vitro and in vivo models for IPF.
5. Clinical trials: Research focused on conducting clinical trials to test the effectiveness of precision medicine-based treatments for IPF, utilizing the therapeutic targets and biomarkers identified through multi-omics data.
6. Understanding the underlying mechanisms of the disease: Research focused on understanding the underlying mechanisms of IPF, with the aim of identifying new potential therapeutic strategies.
7. Multi-omics data integration: Research focused on developing new methods to integrate and analyze multi-omics data to increase the understanding of the disease and identify new biomarkers.
8. Machine learning and AI-based approaches: Research focused on developing machine learning and AI-based approaches to analyze multi-omics data and identify new biomarkers and therapeutic targets.
It is now well-established that both innate and adaptive immune response plays an important role in the pathology of IPF. This Research Topic aims to investigate the use of a multi-omics-based translational approach for precision medicine in IPF. This approach will involve the integration of multiple omics data -including genomics, transcriptomics, proteomics, and metabolomics- to gain a comprehensive understanding of the molecular mechanisms underlying IPF and to identify new therapeutic targets and biomarkers -including diagnostic, prognostic, subtype, drug-response, and side-effect-prediction biomarkers-.
In this Research Topic, we welcome research proposals focused on the use of multi-omics-based translational approaches for precision medicine in Idiopathic Pulmonary Fibrosis (IPF), including immune component analysis (immune cell, immune communication, cytokine, chemokine, and antigens analysis), in vitro and in vivo assays, significant computational methods, and platforms, successful applications, benchmarking datasets, workflows and pipelines, and integrative analysis of high-throughput datasets in this field. The Research Topic will cover, but is not limited to, the following:
1. Identification of novel therapeutic targets: Research focused on identifying new targets for treating IPF using multi-omics data, such as genome-wide association studies, transcriptomics, proteomics, and metabolomics.
2. Development of multi-omics-based diagnostic tests: Research focused on developing diagnostic tests that utilize multi-omics data to aid in diagnosing IPF.
3. Identification of biomarkers for IPF: Research focused on identifying biomarkers that can be helpful for the diagnosis and prognosis of subtype IPF using multi-omics data.
4. In vitro and in vivo validation of therapeutic targets: Research focused on validating novel therapeutic targets identified in multi-omics data using in vitro and in vivo models for IPF.
5. Clinical trials: Research focused on conducting clinical trials to test the effectiveness of precision medicine-based treatments for IPF, utilizing the therapeutic targets and biomarkers identified through multi-omics data.
6. Understanding the underlying mechanisms of the disease: Research focused on understanding the underlying mechanisms of IPF, with the aim of identifying new potential therapeutic strategies.
7. Multi-omics data integration: Research focused on developing new methods to integrate and analyze multi-omics data to increase the understanding of the disease and identify new biomarkers.
8. Machine learning and AI-based approaches: Research focused on developing machine learning and AI-based approaches to analyze multi-omics data and identify new biomarkers and therapeutic targets.
Keywords: idiopathic pulmonary fibrosis, multi-omics, precision medicine, biomarker, therapeutic target
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
